Alumis Inc

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.

– Presented data at EADV supporting potential of ESK-001 as differentiated oral treatment in immune-mediated diseases through maximal TYK2 inhibition – – Continued to advance three clinical programs, including global Phase 3 ONWARD clinical trials for ESK-001 in moderate-to-severe plaque psoriasis, Phase 2b clinical trial for ESK-001 in systemic lupus erythematosus (SLE) and Phase 1 clinical study for A-005 being developed for neuroinflammatory and neurodegenerative diseases – SOUTH SAN FRANCISCO, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today reported financial results for the third quarter ended September 30, 2024, and highlighted recent achievements and upcoming milestones.

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

Bristol-Myers

HC Wainwright has initiated coverage on Alumis Inc. ALMS, a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases.

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside

With a drug in advanced testing for two different indications that have spawned several blockbuster drugs, could Alumis be the next immunology stock to soar on the Nasdaq? Investors who buy now can get it around 30% under the June 28th IPO price. Alumis is backed by prominent healthcare hedge funds such as Baker Brothers, VenBio, and Cormorant Asset Management.

Alumis: Could This Broken Immunology IPO Become The Next Amgen?

28-week data show ESK-001 was generally well tolerated and most patients treated with the top dose of 40 mg twice daily achieved PASI 75 Three additional data presentations further support ESK-001's potential to offer a highly differentiated and best-in-class treatment profile for people with moderate-to-severe plaque psoriasis Full 52-week Phase 2 OLE dataset expected 1H 2025; Phase 3 clinical program ongoing SOUTH SAN FRANCISCO, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced positive 28-week data from the open-label extension (OLE) period of its Phase 2 STRIDE clinical trial of ESK-001.

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

Alumis, a recent IPO, has ESK-001, a promising phase 3 TYK2 inhibitor for Psoriasis and SLE, showing superior efficacy and safety over existing treatments. ESK-001's allosteric inhibition offers high selectivity and minimal off-target effects, potentially positioning it as a better alternative to the approved TYK2 inhibitor, Sotyktu. Despite strong midstage trial data and a solid cash runway, the highly competitive market and recent IPO status present significant investment risks.

Alumis: Recent IPO With Differentiated Data In Autoimmune Diseases

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that company management will participate in the following investor conferences in September: Morgan Stanley 22nd Annual Global Healthcare ConferenceThursday, September 5, 2024, 8:30 am ETNew York, NY Format: fireside chat and one-on-one investor meetings 2024 Wells Fargo Healthcare ConferenceFriday, September 6, 2024Boston, MA Format: one-on-one investor meetings only Baird 2024 Global Healthcare ConferenceWednesday, September 11, 2024, 8:30 am ETNew York, NY Format: presentation and one-on-one investor meetings; archived webcast replay on Investor Events page of Alumis website for 90 days following the conference 2024 Cantor Fitzgerald Global Healthcare ConferenceTuesday, September 17, 2024, 10:55 am ETNew York, NY Format: fireside chat and one-on-one investor meetings; live webcast on Investor Events page of Alumis website, archived replay available for 90 days following the presentation Stifel 2024 Immunology and Inflammation Virtual SummitWednesday, September 18, 2024, 10:00 am ET Format: presentation About Alumis Alumis is a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases.

Alumis to Participate in Upcoming September Investor Conferences

– Initiated patient dosing in ESK-001 Phase 3 ONWARD clinical program in moderate-to-severe plaque psoriasis – – Initiated Phase 1 clinical trial for A-005 in healthy participants – – Completed IPO and private placement raising gross proceeds of $250M – SOUTH SAN FRANCISCO, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today reported financial results for the second quarter ended June 30, 2024, and provided a summary of recent corporate achievements and upcoming milestones.

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

– Co-primary endpoint of PASI 75 and sPGA 0/1 score at 24 weeks to serve as basis for U.S. regulatory submission – – Pivotal Phase 3 program supported by positive Phase 2 STRIDE clinical data as well as ongoing open-label extension (OLE) study – – Topline data anticipated in 2026 – SOUTH SAN FRANCISCO, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that patient dosing has commenced in the ONWARD Phase 3 clinical program.

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

Guggenheim Partners initiated coverage on Alumis Inc. ALMS, a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases.

Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation

Landbridge Co LLC

Lineage Inc

TWFG Inc

WEBTOON Entertainment Inc.

YSX Tech Co Ltd

The IPO market closed out June with four deals, three of which raised $100+ million. In the pipeline, nine companies submitted initial filings, led by what could be the largest IPO of 2024 to date. Web comic platform WEBTOON Entertainment (WBTN) led the week's deals, pricing at the high end to raise $315 million at a $2.8 billion market cap.

U.S. IPO Weekly Recap: 2Q IPO Market Closes Out With Sizable Pricings And Pipeline Additions

On Friday, Alumis Inc ALMS priced its initial public offering at $16/share, the low end of the range of $16 to $18, raising $210 million via 13.13 million shares offering.

Immune Disease-Focused Alumis Raises $250M In Downsized Initial Public Offering

Shares of biopharmaceutical firm Alumis opened nearly 16% below their initial public offering (IPO) price in their debut on the Nasdaq on Friday.

Biopharma firm Alumis' shares fall nearly 16% in Nasdaq debut

Alumis set the pricing of its U.S. initial public offering at $16 per share, the lower end of its price range, valuing it at around $902 million.

Therapy developer Alumis prices U.S. IPO at about $902 mln valuation

Alumis, a clinical-stage biopharmaceutical company developing oral therapies for immune mediated diseases, announces pricing of initial public offering

Alumis Announces Pricing of Initial Public Offering

Alumis is targeting a valuation of up to $1.01 billion in its initial public offering in the United States, the therapy developer said on Monday.

Therapy developer Alumis seeks up to $1 bln valuation in US IPO

Biopharmaceutical company Alumis Inc. on Monday said it plans to offer 17.65 million shares at an estimated price range of $16 to $18 a share in its upcoming initial public offering. At the midpoint of its range, Alumis will raise about $300 million with underwriters ​Morgan Stanley, Leerink Partners​​, Cantor and ​​Guggenheim Securities.

Alumis eyes $300 million in proceeds in IPO

Alumis Inc. has filed for a $100 million IPO to advance its later-Phase trials treatment programs. Lead candidate ESK-001 shows positive trial results for psoriasis treatment, driving potential demand for company shares. The global psoriasis treatment market forecasted to reach $44 billion by 2031, with Alumis seeking U.S. public capital market investment.

Alumis' $100 Million IPO: Promising Psoriasis Treatment Results

News for Alumis Inc Stock (ALMS)